Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas.

Published on Jul 10, 2021in Endocrine Journal2.349
· DOI :10.1507/ENDOCRJ.EJ21-0106
Cyndy Liu (U of A: University of Alberta), Tae Nakano-Tateno4
Estimated H-index: 4
(U of A: University of Alberta)
+ 2 AuthorsToru Tateno15
Estimated H-index: 15
(U of A: University of Alberta)
Sources
Abstract
Pituitary adenomas are benign tumours that can cause an individual various clinical manifestations including tumour mass effects and/or the diverse effects of abnormal pituitary hormone secretion. Given the morbidity and limited treatment options for pituitary adenomas, there is a need for better biomarkers and treatment options. One molecule that is of specific interest is the signal transducer and activator of transcription 3 (STAT3), a transcription factor that plays a critical role in mediating cytokine-induced changes in gene expression. In addition, STAT3 controls cell proliferation by regulating mitochondrial activity. Not only does activation of STAT3 play a crucial role in tumorigenesis, including pituitary tumorigenesis, but a number of studies also demonstrate pharmacological STAT3 inhibition as a promising treatment approach for many types of tumours, including pituitary tumours. This review will focus on the role of STAT3 in different pituitary adenomas, in particular, growth hormone-producing adenomas and null cell adenomas. Furthermore, how STAT3 is involved in the cell proliferation and hormone regulation in pituitary adenomas and its potential role as a molecular therapeutic target in pituitary adenomas will be summarized.
📖 Papers frequently viewed together
References0
Newest
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.